Disease · EFO_0803536
Comparisons in its trials277
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 277
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| IFN Beta-1a 30 mcg vs DAC HYP 150 mg: serious adverse events | 194 of 922 | 221 of 919 | 1,841 | NCT01064401 | Trial comparisons |
| BG00012 240 mg BID vs BG00012 240 mg TID: Number of Participants With Treatment-Emergent Adverse Events (AEs) | 824 of 868 | 814 of 868 | 1,736 | NCT00835770 | Trial comparisons |
| BG00012 240 mg BID vs BG00012 240 mg TID: deaths from any cause | 5 of 868 | 6 of 868 | 1,736 | NCT00835770 | Trial comparisons |
| BG00012 240 mg BID vs BG00012 240 mg TID: serious adverse events | 279 of 868 | 272 of 868 | 1,736 | NCT00835770 | Trial comparisons |
| Active Treatment Phase: Laquinimod 0.6 mg vs Active Treatment Phase: Laquinimod 1.2 mg: Active Treatment Phase: Number of Participants With Potentially Clinically Significant Abnormal Serum Chemistry | 887 of 891 | 501 of 504 | 1,395 | NCT01707992 | Trial comparisons |
Active Treatment Phase: Laquinimod 0.6 mg vs Active Treatment Phase: Laquinimod 1.2 mg: Active Treatment Phase: Number of Participants With Potentially Clinically Significant Abnormal Hematology Values | 886 of 891 | 499 of 504 | 1,395 | NCT01707992 | Trial comparisons |
| Active Treatment Phase: Laquinimod 0.6 mg vs Active Treatment Phase: Laquinimod 1.2 mg: Active-Treatment Phase: Number of Participants With AEs | 442 of 891 | 241 of 504 | 1,395 | NCT01707992 | Trial comparisons |
| Active Treatment Phase: Laquinimod 0.6 mg vs Active Treatment Phase: Laquinimod 1.2 mg: Active-Treatment Phase: Number of Participants With Clinically Significant Vital Signs Abnormalities | 17 of 891 | 7 of 504 | 1,395 | NCT01707992 | Trial comparisons |
| IFN β-1a 30 µg (301)/DAC HYP 150 mg (303) vs DAC HYP 150 mg (301) /DAC HYP 150 mg (303): Number of Participants Who Are Free From Disease Activity in the 205MS303 Treatment Period | 9 of 597 | 7 of 606 | 1,203 | NCT01797965 | Trial comparisons |
| IFN β-1a 30 µg (301)/DAC HYP 150 mg (303) vs DAC HYP 150 mg (301) /DAC HYP 150 mg (303): Number of Participants With Relapse in the 205MS301-303 Combined Study Period | 339 of 597 | 261 of 606 | 1,203 | NCT01797965 | Trial comparisons |
| IFN β-1a 30 µg (301)/DAC HYP 150 mg (303) vs DAC HYP 150 mg (301) /DAC HYP 150 mg (303): Number of Participants With Sustained Disability Progression in the 205MS301-303 Combined Study Period | 144 of 597 | 130 of 606 | 1,203 | NCT01797965 | Trial comparisons |
| Teriflunomide vs Evobrutinib: deaths from any cause | 0 of 583 | 0 of 581 | 1,164 | NCT04338061 | Trial comparisons |
| Teriflunomide vs Evobrutinib: serious adverse events | 37 of 583 | 51 of 581 | 1,164 | NCT04338061 | Trial comparisons |
| Glatiramer Acetate 20 mg vs Glatiramer Acetate 40 mg: serious adverse events | 25 of 586 | 24 of 569 | 1,155 | NCT00337779 | Trial comparisons |
| Ponesimod 20 mg vs Teriflunomide 14 mg: deaths from any cause | 0 of 565 | 2 of 566 | 1,131 | NCT02425644 | Trial comparisons |
| Ponesimod 20 mg vs Teriflunomide 14 mg: serious adverse events | 49 of 565 | 46 of 566 | 1,131 | NCT02425644 | Trial comparisons |
| Teriflunomide vs Evobrutinib: deaths from any cause | 1 of 563 | 1 of 559 | 1,122 | NCT04338022 | Trial comparisons |
| Teriflunomide vs Evobrutinib: serious adverse events | 33 of 563 | 45 of 559 | 1,122 | NCT04338022 | Trial comparisons |
| Laquinimod 0.6 mg vs Placebo: deaths from any cause | 0 of 550 | 3 of 556 | 1,106 | NCT00509145 | Trial comparisons |
| Laquinimod 0.6 mg vs Placebo: serious adverse events | 61 of 550 | 53 of 556 | 1,106 | NCT00509145 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0803536/comparisons